
Twelve years of multiples investors have paid for Acutaas Chemicals Limited, framed against the sector median so the premium or discount is obvious at a glance.
Acutaas Chemicals Limited trades at a P/E of 75.61× and P/B of 16.29×.
Auto-detected classical chart patterns for Acutaas Chemicals Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Twelve years of audited numbers for Acutaas Chemicals Limited, switchable between annual and quarterly views, consolidated or standalone.
Acutaas Chemicals Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,67,60,39,49,369.2 Cr and reported EPS of ₹35.07.
| Period | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue from Operations | 520 | 617 | 717 | 1,007 | 1,339 |
| Other Income | 3 | 4 | 7 | 17 | 42 |
| Total Income | 523 | 621 | 725 | 1,024 | 1,381 |
| Cost of Goods Sold (COGS) | 273 | 331 | 412 | 552 | 566 |
| Gross Profit | 247 | 286 | 306 | 455 | 773 |
| +Operating Expenses | 142 | 163 | 177 | 223 | 293 |
| EBITDA | 105 | 123 | 128 | 232 | 480 |
| +Non-Operating Expenses | 16 | 15 | -10 | 33 | 39 |
| Profit Before Tax (PBT) | 91 | 112 | 82 | 216 | 483 |
| +Tax Expense | 20 | 29 | 33 | 56 | 126 |
| Total Profit for Period | 72 | 83 | 49 | 160 | 356 |
| Less: Non-controlling Interests | — | — | 6 | 2 | 0 |
| Net Profit (Owner's PAT) | 72 | 83 | 43 | 159 | 356 |
| Earnings Per Share (EPS) | 9.87 | 11.43 | 5.80 | 19.39 | 43.51 |
| Diluted Shares Outstanding (Nos.) | 7 | 7 | 7 | 8 | 8 |
| +Additional Disclosures | 706 | 843 | 1,021 | 1,361 | 1,461 |
| Sales Growth % | — | 18.57 | 16.33 | 40.34 | 33.02 |
| YoY Sales Growth % | — | 18.57 | 16.33 | 40.34 | 33.02 |
| Material Cost % | 54 | 56 | 61 | 57 | 44 |
| Employee Cost % | 8 | 8 | 9 | 8 | 9 |
| Other Cost % | 19 | 19 | 16 | 14 | 13 |
| OPM % | 20 | 20 | 18 | 23 | 36 |
| Tax % | 21 | 26 | 41 | 26 | 26 |
| Profit Growth % | — | 15.77 | -48.65 | 271.06 | 124.46 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| +Additional Fields | 95 | 110 | 112 | 205 | 444 |
Disclosed business segments at Acutaas Chemicals with their share of revenue and profit, switchable between consolidated and standalone reporting.
Acutaas Chemicals discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Our AI distills the core fundamental drivers supporting Acutaas Chemicals Limited, the risks that threaten it, and the exact valuation or growth triggers that should make you re-evaluate.
Acutaas Chemicals Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
Outstanding quarterly profit growth of 93.50% demonstrates strong operational efficiency.
Robust quarterly sales growth of 24.10% indicates increasing market penetration.
Healthy OPM 27.30%, ROCE 19.90%, ROE 16.00% reflect strong profitability.
Very low debt-to-equity ratio of 0.01 signifies robust financial health.
Significant increase in FII/DII holdings shows growing institutional investor confidence.
High P/E ratio of 61.49 suggests potential overvaluation compared to peers.
Decreasing promoter holding from 41.05% to 32.66% may signal insider concerns.
Very low dividend yield of 0.09% may not attract income investors.
High price-to-book value of 9.74 implies significant overvaluation.
Recent 5-day price decline of -2.47% indicates short-term stock volatility.
Trim if P/E re-rates above 98. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 19%. The operating engine is no longer compounding capital efficiently.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Acutaas Chemicals Limited is highlighted for quick read-across.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Acutaas Chemicals Limited — derived from the live tape, not yesterday's close.
Acutaas Chemicals Limited last traded at ₹3,268.6 with an intraday range of ₹3,233.8–₹3,319.6 — live indicator, pivot and CPR signals below.
Standard pivot — most widely referenced.
| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 3485.80 | +217.20 | +6.65% |
| R3 | 3400.00 | +131.40 | +4.02% |
| R2 | 3359.80 | +91.20 | +2.79% |
| R1 | 3314.20 | +45.60 | +1.40% |
| PIVOT | 3274.00 | 5.40 | 0.17% |
| CURRENT | 3268.60 | — | — |
| S1 | 3056.80 | -211.80 | -6.48% |
| S2 | 3142.60 | -126.00 | -3.85% |
| S3 | 3188.20 | -80.40 | -2.46% |
| S4 | 3228.40 | -40.20 | -1.23% |
ACUTAAS is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: 3278 ~ 3319.6
Trading Inside opening range
Daily traded volume and delivery percentage for Acutaas Chemicals Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Acutaas Chemicals Limited stood at 56.2% of traded volume, against a 20-day average of 43.8%.
Filings Acutaas Chemicals sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Acutaas Chemicals files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 130 documents below.
Acutaas Chemicals Limited has informed the Exchange about Investor Presentation
Acutaas Chemicals Limited has informed the Exchange about Transcript
Acutaas Chemicals Limited has informed the Exchange about Copy of Newspaper Publication
Acutaas Chemicals Limited has informed the Exchange about Link of Recording
Acutaas Chemicals Limited has informed the Exchange about General Updates - Board approves Final Dividend
Promoter, director and designated-employee transactions in Acutaas Chemicals as reported to SEBI — buying and selling signals from the people who know the business best.
Acutaas Chemicals insider activity below tracks 6 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Vijay Gosar | Insider | 27 Feb 2026 | buy | +500 | ₹10.72 L | ₹2,144.26 |
| Vijay Gosar | Insider | 27 Feb 2026 | buy | +500 | ₹10.72 L | ₹2,144.26 |
| Vijay Gosar | Insider | 27 Feb 2026 | buy | +500 | ₹10.72 L | ₹2,144.26 |
| Chetankumar Chhaganlal Vaghasia | Insider | 19 May 2025 | sell | −13.49 L | ₹150.4 Cr | ₹1,115.00 |
| NARESHKUMAR RAMJIBHAI PATEL | Insider | 19 May 2025 | sell | −13.49 L | ₹150.4 Cr | ₹1,115.00 |
| RAM MOHAN LOKHANDE | Insider | 31 Dec 2024 | sell | −400 | ₹8.52 L | ₹2,130.00 |
Every dividend, stock split and bonus issue Acutaas Chemicals has declared, sequenced by announce and record date.
Acutaas Chemicals corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
What Acutaas Chemicals Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Acutaas Chemicals Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: ACUTAAS, BSE: 543349.

Acutaas Chemicals Limited is a prominent player in the pharmaceutical and specialty chemicals industry, headquartered in Surat, India. The company's core business revolves around the research, development, manufacturing, and global distribution of pharmaceutical intermediates. These intermediates serve as crucial building blocks for the synthesis of various active pharmaceutical ingredients (APIs).
Acutaas's pharmaceutical intermediate portfolio caters to a broad spectrum of therapeutic areas. Their products are integral components in the production of APIs for medications targeting conditions such as retroviral infections, inflammatory diseases, psychotic disorders, cancer, Parkinson's disease, depression, and blood clotting disorders. This highlights their significant contribution to the development and manufacture of essential medicines.
Beyond pharmaceutical applications, Acutaas Chemicals Limited also produces a range of specialty chemicals. These find applications in diverse sectors including agrochemicals (pesticides and herbicides), cosmetics, and polymers (plastics and resins). Specifically, they manufacture and supply parabens (used as preservatives), salicylic acid (with applications in various industries), and other custom-synthesized chemicals for various industrial uses. This diversification broadens their customer base and revenue streams.
The company's international reach is notable, with a significant portion of its production exported globally. This demonstrates their capability to meet international quality standards and successfully compete in a highly competitive global market. The company's history, dating back to its founding in 2004 as Ami Organics Limited and rebranding in May 2025, suggests a track record of growth and adaptation within the industry.
In summary, Acutaas Chemicals Limited operates as a vertically integrated chemical company. Their business model encompasses the entire value chain, from research and development to the global marketing and sales of diverse chemical products. Their focus on pharmaceutical intermediates, coupled with their expertise in specialty chemicals, positions them strategically within the rapidly evolving global chemical landscape.
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
The current share price of Acutaas Chemicals Limited (ACUTAAS) is ₹3,268.6. Today, the stock has declined by ₹8.60 (0.26%), trading in a range of ₹3,233.8 to ₹3,319.6. The stock opened at ₹3,301.4 with a trading volume of 2,83,229 shares.
Acutaas Chemicals Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,67,60,39,49,369.2 crores, P/E ratio of 75.61, ROE of 23.52%, and ROCE of 19.90%. The dividend yield stands at 0.05%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Acutaas Chemicals Limited (ACUTAAS) is ₹3,444.3, while the 52-week low is ₹1,059. Currently trading at ₹3,268.6, the stock is 92.6% away from its 52-week low and 5.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Acutaas Chemicals Limited stock at ₹3,268.6 depends on multiple factors. The stock is currently trading with a P/E ratio of 75.61 and P/B ratio of 16.29. Today's performance shows a loss of 0.26%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Acutaas Chemicals Limited offers a dividend yield of 0.05%, which means for every ₹100 invested at the current price of ₹3,268.6, you can expect to receive approximately ₹0.05 annually as dividends. The face value of the stock is ₹0.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Acutaas Chemicals Limited's key financial metrics include: P/E Ratio: 75.61, P/B Ratio: 16.29, ROE: 23.52%, ROCE: 19.90%, Dividend Yield: 0.05%, EPS: ₹35.07, Book Value: ₹201.93, and Debt-to-Equity: 0.02. The company's market cap stands at ₹2,67,60,39,49,369.2 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Acutaas Chemicals Limited stock opened at ₹3,301.4 and is currently trading at ₹3,268.6, showing a decline of ₹8.60 (0.26%). The intraday high is ₹3,319.6 and low is ₹3,233.8. The trading volume stands at 2,83,229 shares, indicating moderate market participation today.
Acutaas Chemicals Limited has a Price-to-Earnings (P/E) ratio of 75.61, which means investors are willing to pay ₹75.61 for every ₹1 of earnings. With an EPS of ₹35.07, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Acutaas Chemicals Limited (ACUTAAS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Peers, sector trends, screeners and strategy playbooks contextual to this stock.